Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Long-Term Debt Repayments (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Long-Term Debt Repayments for 14 consecutive years, with $278000.0 as the latest value for Q4 2025.

  • Quarterly Long-Term Debt Repayments changed N/A to $278000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $642000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $985000.0 for FY2024, 4.74% down from the prior year.
  • Long-Term Debt Repayments hit $278000.0 in Q4 2025 for Vistagen Therapeutics, up from $274000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $785000.0 in Q3 2023 to a low of -$1000.0 in Q4 2023.
  • Historically, Long-Term Debt Repayments has averaged $250863.6 across 4 years, with a median of $274000.0 in 2025.
  • Biggest five-year swings in Long-Term Debt Repayments: soared 12212.5% in 2021 and later tumbled 100.32% in 2023.
  • Year by year, Long-Term Debt Repayments stood at $98500.0 in 2021, then surged by 215.53% to $310800.0 in 2022, then crashed by 100.32% to -$1000.0 in 2023, then skyrocketed by 27900.0% to $278000.0 in 2025.
  • Business Quant data shows Long-Term Debt Repayments for VTGN at $278000.0 in Q4 2025, $274000.0 in Q3 2025, and $90000.0 in Q2 2025.